On September 1, 2026 Cellectis (the "Company") (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, reported that it will participate in the upcoming investor conferences :

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference – Boston, MA

September 10, 2026

Baird 2026 Global Healthcare Conference – New York

September 15, 2026

Company presentation at 12:50 – 1:20 p.m. ET

Fall Focus: Barclays Biotech 1×1 Day – New York

October 6, 2026

Stifel 2026 Healthcare Conference – New York

November 10-12, 2026

Jefferies Global Healthcare Conference – London

November 16-19, 2026

Cellectis’ management team will be available for meetings with investors throughout these conferences. To arrange a meeting, please contact the respective conference representatives or Cellectis Investor Relations at [email protected]

Any available webcast will be posted to the Company’s website at View Source

(Press release, Cellectis, SEP 1, 2026, View Source [SID1234670481])